Navigation Links
Mayo researchers: Dramatic outcomes in prostate cancer study
Date:6/19/2009

ROCHESTER, Minn. -- Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the abdominal areas.

"The goal of the study was to see if we could modestly improve upon current treatments for advanced prostate cancer," says Eugene Kwon, M.D., Mayo Clinic urologist and leader of the clinical trial. "The candidates for this study were people who didn't have a lot of other options. However, we were startled to see responses that far exceeded any of our expectations."

The patients first received a type of hormone therapy called androgen ablation, which removes testosterone and usually causes some initial reduction in tumor size. Researchers then introduced a single dose of ipilimumab, an antibody, which builds on the anti-tumor action of the hormone and causes a much larger immune response, resulting in massive death of the tumor cells. Both men experienced consistent drops in their prostate specific antigen (PSA) counts over the following weeks until both were deemed eligible for surgery. Then, during surgery, came a greater surprise.

"The tumors had shrunk dramatically," says Michael Blute, M.D., Mayo urologist, co-investigator and surgeon, who operated on both men. "I had never seen anything like this before. I had a hard time finding the cancer. At one point the pathologist (who was working during surgery) asked if we were sending him samples from the same patient."

One patient underwent radiation therapy after surgery; both have resumed their regular lives. Further research is being planned to understand more about the mechanisms of the antibody and how best to use the approach in practice. The researchers, however, note the significance of their findings.

"This is one of the holy grails of prostate cancer research," says Dr. Kwon. "We've been looking for this for years."


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
2. Children Tell Researchers: Well Get Fit if Its Fun
3. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
4. Researchers: Program discourages HIV transmission in Russia
5. Attacks against medical researchers: Time to take a stand
6. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
7. Mayo researchers: complementary therapies help patients recover after heart surgery
8. OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
9. Mercury in Mackenzie River delta dramatically higher than previously believed
10. Cinergy Health Expands Staff in Face of Dramatic Growth
11. Study Results Show CAQH CORE Certification Dramatically Cuts Administrative Costs, Accelerates I.T. Adoption by Providers and Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the ... a new blog post about women’s hair loss. Although hair transplant procedures can be ... they age. Menopause or genetics can be two reasons a woman may see her ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want ... their missing teeth can now have them placed by Dr. Manju Kejriwal, with or ... Cone Beam technology to increase the accuracy of each dental implant placement. The i-CAT ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global flow cytometry ... by 2025, according to a new study by Grand ... and cancer is expected to upsurge the demand for ... coming years. In addition, higher number of physicians is ... cell therapy, due to adverse effects caused by chemotherapy ...
(Date:3/27/2017)... , March 27, 2017 The ... digital health and data analytics company, signed a ... for improving healthcare delivery in the region. ... for Global Health Research and Technology (BIGHEART) at ... on several topics related to healthcare IT and ...
(Date:3/27/2017)... 27, 2017 Therapix Biosciences ... company specializing in the development of cannabinoid-based drugs, today ... the United States of ... 40 ordinary shares of the Company, at a ... has granted the underwriters a 45-day over-allotment option ...
Breaking Medicine Technology: